Indeed, faculty in the Division led the way in rapidly transitioning our practices to telehealth and in developing innovative treatment regimens for diabetes in patients with COVID-19. In addition, Ronald Tamler, MD, trained more than 1,000 clinicians in telehealth, a vital tool in ensuring patient and physician safety. And Zijian Chen, MD, is the founding director of the nation’s first Center for Post-COVID Care.
Research advances have continued unabated. My colleagues and I identified two distinct subtypes of polycystic ovary syndrome associated with novel gene regions. Terry Davies, MD, and his research team created human thyroid cells from dermal fibroblasts with the ability to secrete thyroid hormone. Alice Levine, MD, led an innovative study of the use of GnRH antagonists to treat adrenal tumors. Andrew Stewart, MD, and his group continued to make significant progress in investigating beta cell regeneration for treatment of diabetes. Mone Zaidi, MD, and his group investigated FSH-blocking therapies as a modality to reduce obesity and bone loss.
Carol Levy, MD, and colleagues are leading a multicenter trial that is tailoring a continuous glucose monitoring system to the unique challenges faced by pregnant women with type 1 diabetes. Last but not least, The Mount Sinai Hospital was again nationally ranked by U.S. News and World Report in diabetes and endocrinology.
I am very proud to have the privilege of working with these dedicated physicians and scientists who have prevailed in the face of the most challenging health crisis in more than a century. I invite you to learn more about the Division’s exciting clinical and research initiatives in the following articles.
Andrea Dunaif, MD
Chief of the Hilda and J. Lester Gabrilove Division of Endocrinology, Diabetes and Bone Disease, and the Stratton Professor of Molecular Medicine